Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 12, 2012, Pages 1439-1446

  Antonela Antoniu, Sabina ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

chronic obstructive pulmonary disease; ciprofloxacin; cystic fibrosis bronchiectasis; inhaled antibiotics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ARIKACE; AZTREONAM; AZTREONAM LYSINE; CHOLESTEROL; CIPROFLOXACIN; COLISTIMETHATE; FOSFOMYCIN; LEVOFLOXACIN; LIPOSOME; MANNITOL; NEBCINAL; PHOSPHOLIPID; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED RELEASE FORMULATION; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG LUNG LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRY POWDER; DYSGEUSIA; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; INFECTION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POWDER INHALER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SPRAY DRYING; TENDINITIS; TENDON RUPTURE;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CIPROFLOXACIN; CLINICAL TRIALS AS TOPIC; HUMANS; LIPOSOMES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84871448900     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.136     Document Type: Review

References (38)

1. Hubert D, Leroy S, Nove-Josserand R et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J. Cyst. Fibros. 8(5), 332-337 (2009).
2. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir. Care 54(5), 658-670 (2009).
3. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir. Care 54(5), 628-640 (2009).
4. Bals R, Hubert D, Tümmler B. Antibiotic treatment of CF lung disease: From bench to bedside. J. Cyst. Fibros. 10(Suppl. 2), S146-S151 (2011).
5. Flume PA, O'Sullivan BP, Robinson KA et al.; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957-969 (2007). (Pubitemid 350127838)
6. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr. Pulmonol. doi:10.1002/ppul.21546 (2010) (Epub ahead of print).
7. European Medicines Agency. Cayston: EPAR Y Product Information, Annex I Y summary of product characteristics. 8 European Medicines Agency. Colobreathe: EPAR product information (2012).
8. Garcia-Vidal C, Almagro P, Romaní V et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: A prospective study. Eur. Respir. J. 34(5), 1072-1078 (2009).
9. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132(5), 1565-1572 (2007). (Pubitemid 350156014)
10. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother. 64(2), 229-238 (2009).
11. Jain M, Bar-Meir M, McColley S et al. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: A paradigm of chronic infection. Transl. Res. 152(6), 257-264 (2008).
12. Konstan MW, Morgan WJ, Butler SM et al.; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J. Pediatr. 151(2), 134-139, 139.e1 (2007).
13. Van De Weert-Van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CL, Van Der Ent CK, Arets HG. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur. Respir. J. 39(4), 893-898 (2012).
14. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999). (Pubitemid 29024680)
15. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax 65(4), 286-291 (2010).
16. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 165(9), 847-856 (2011).
17. CIPRO® (ciprofloxacin hydrochloride) tablets, prescribing information. Bayer AG, Leverkusen, Germany (1987).
18. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 68(1), 223-240 (2008). (Pubitemid 351363790)
19. Krieg DP, Helmke RJ, German VF, Mangos JA. Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect. Immun. 56(12), 3173-3179 (1988).
20. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36(2), 78-91 (2006). (Pubitemid 43294628)
21. Chono S, Tanino T, Seki T, Morimoto K. Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab. Pharmacokinet. 22(2), 88-95 (2007).
22. Chono S, Tanino T, Seki T, Morimoto K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target. 14(8), 557-566 (2006). (Pubitemid 44592889)
23. Chono S, Tanino T, Seki T, Morimoto K. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev. Ind. Pharm. 34(10), 1090-1096 (2008).
24. Ong HX, Traini D, Bebawy M, Young PM. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm. Res. 28(9), 2327-2338 (2011).
25. Adi H, Young PM, Chan HK, Agus H, Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 40(3), 239-247 (2010).
26. Stass H, Baumann-Noss S, Delessen H, Nagelschmitz J, Willmann S, Edington A. Ciprofloxacin pulmosphere inhalational powder: A healthy volunteer study. Presented at: The American Thoracic Society International Conference. Toronto, ON, USA, 16-21 May 2008.
27. Tokimatsu I, Hiramatsu K, Morimoto T et al. Safety, tolerability and pharmacokinetics of a single dose of ciprofloxacin dry powder for inhalation in Japanese patients with mild to moderate chronic obstructive pulmonary disease: A randomized controlled trial. Am. J. Respir. Crit. Care Med. 183, Abstract A3105 (2011).
28. Stass H, Badorrek P, Hohlfeld J, Krug N, Nagelschmitz J, Welte T. Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD. Eur. Respir. J. 38(Suppl. 55), Abstract 3011 (2011).
29. Stass H, Dalhoff A. Ciprofloxacin inhale Y a pharmacokinetic (PK)/pharmacodynamic (PD) rationale. Am. J. Respir. Crit. Care Med. 181, Abstract A1820 (2010).
30. Leclerq R, Cantón R, Giske C et al.; European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST Expert rules in antimicrobial susceptibility testing: Version 1 (2008).
31. Wilson R, Welte T, Polverino E et al. Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Eur. Respir. J. 38(Suppl. 55), 334s (2011).
32. Alder JWR, Welte T, Polverino E et al. Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Eur. Respir. J. 38(Suppl. 55), 334sY335s (2011).
33. Bilton D, Serisier DJ, De Soyza AT, Wolfe R, Bruinenberg P. Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Eur. Respir. J. 38(Suppl. 55), 333s (2011).
34. Serisier D, Thompson PJ, Greville H, Kolbe J, Bruinenberg PR. Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE).Eur. Respir. J. 38(Suppl. 55), 334s (2011).
35. Sordé R, Pahissa A, Rello J. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect. Drug Resist. 4, 31-41 (2011).
36. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9, 32 (2011).
37. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: A systematic review. Arch. Dis. Child. 96(9), 874-880 (2011).
38. Owens RC Jr, Ambrose PG. Antimicrobial safety: Focus on fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S144-S157 (2005). (Pubitemid 40962485)